( SAN FRANCISCO & NEW DELHI India--(...)Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine,Health

SAN FRANCISCO & NEW DELHI, India--(BUSINESS WIRE)--Jun 21, 2007 - The Institute for OneWorld Health, a US-based non-profit pharmaceutical company, today announced that Phase 3 research related to its first approved drug product, Paromomycin IM Injection (Paromomycin), was published in the current issue of The New England Journal of Medicine (NEJM). This clinical trial shows that the medicine paromomycin is safe, effective, and well suited to curing visceral leishmaniasis (VL), the world's second most deadly parasitic disease after malaria.

The Institute for OneWorld Health, working closely with the Indian Council for Medical Research (ICMR) sponsored the clinical trial in collaboration with the Special Programme for Research and Training in Tropical Diseases (TDR), a Geneva-based international organization sponsored by UNICEF, UNDP, the World Bank and the World Health Organization. The clinical trial was established with funding from the Bill & Melinda Gates Foundation.

Gland Pharma Limited, the Hyderabad, India-based drug manufacturer, working with OneWorld Health and other collaborators, received regulatory approval from the Drug-Controller General - India (DCGI) for Paromomycin IM Injection as a treatment for VL on August 31, 2006. Gland Pharma has agreed to act as the global manufacturer of Paromomycin to ensure access to all those that need it, and at a markedly reduced cost -- currently, approximately $10 USD per 21-day course of therapy.

"The results of this study underscore the potential of Paromomycin to treat VL -- and save lives -- at very low cost and in safe and practical ways," said Dr. Ahvie Herskowitz, co-founder and chief medical officer of the Institute for OneWorld Health. "This research is essential to increasing access to new therapies for this neglected disease, also known as kala-azar and black fever."

With approximately 500,000 new cases occurring annually wo
'"/>

Page: 1 2 3 4
Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Stanford Researchers Find Brain Pathway of Depression in Rats
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
5. Researchers Discover Method for Identifying How Cancer Evades the Immune System
6. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
7. Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries
8. President Bush Ignores Americas Plea for Support of Stem Cell Research
9. Researchers Discover Gene For Rare Skin Disorder
10. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
11. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study